Valneva(US:VALN) Newsfilter·2025-02-18 06:00Core Viewpoint - Valneva SE reported strong preliminary financial results for 2024, achieving double-digit sales growth and a solid cash position, while outlining a positive outlook for 2025 with significant clinical and regulatory advancements expected [4][7][8]. 2024 Performance - Total revenues for 2024 were €169.6 million, a 10% increase from €153.7 million in 2023 [8]. - Product sales revenue reached €163.3 million, reflecting a 13% growth compared to €144.6 million in 2023 [8]. - Year-end cash and cash equivalents stood at €168.3 million, up from €126.1 million in 2023, bolstered by the sale of a Priority Review Voucher and a successful private placement [8]. 2025 Financial Outlook - Sales revenues are projected to grow to between €170 million and €180 million, with total revenues expected to reach €180 million to €190 million [8]. - Total R&D investments are anticipated to be between €90 million and €100 million, partially offset by grant funding and R&D tax credits [8]. - The company expects to maintain a lower operating cash burn of less than €30 million in 2025, compared to over €60 million in 2024 [8]. Regulatory, R&D and Strategic Highlights - Significant clinical and regulatory progress was made in 2024, with multiple anticipated data readouts and product approvals expected in 2025 [7][9]. - The company is advancing its Lyme disease vaccine candidate, VLA15, with the first Phase 3 study results expected by the end of 2025 [6][9]. - Valneva secured three additional regulatory approvals for its chikungunya vaccine, IXCHIQ®, and initiated a Phase 2b trial for a tetravalent Shigella vaccine candidate [9][15]. Key Upcoming Catalysts - The first data readout from the Lyme disease Phase 3 study is anticipated by the end of 2025 [6]. - Phase 2b efficacy data for the Shigella vaccine candidate is expected in mid-2025, along with the launch of a pediatric study [15].